Etching a New Chapter Enterprise AI Solution in the APAC region
Trescon is set to organize the 42nd edition of World AI Show, a global platform…
Trescon is set to organize the 42nd edition of World AI Show, a global platform…
SINGAPORE, Aug 1, 2023 – (ACN Newswire) – The World CX Summit, organized by Trescon,…
WAYNE, Pa.–(BUSINESS WIRE)–Global Tax Management (GTM), a professional services firm focused exclusively on delivering corporate…
Authors Dr. Lisa Langford, Dr. Tiefa Jones and Dr. Alfreda Goods define and explore inclusion…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Syxsense, a leader in Unified Security and Endpoint Management (USEM), has been…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA is pleased to announce the assignment of ratings to eight classes of…
Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market…
Real-world evidence demonstrates the clinical, health equity and patient benefits of AI-powered care coordination. SAN…
MOBILE, Ala.–(BUSINESS WIRE)–CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that Mark V. Anquillare…
The second major release of Alight Worklife for 2023 builds on the platform’s AI foundation,…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
TORONTO, July 31, 2023 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX…
TORONTO, July 31, 2023 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX…
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company…
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company…
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Stable disease was observed in three out of seven heavily pretreated patients No dose-limiting toxicities…
Stable disease was observed in three out of seven heavily pretreated patients No dose-limiting toxicities…